AR and prostate cancer: Fan et al. [28] showed a positive feedback regulatory loop between AR and IGF1 that enhances AR activation, suggesting that pharmacological strategies that reduce IGF1 in combination with antiandrogen therapies may have clinical benefit in fighting prostate cancer.